North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition 2025 guidelines for management of cyclic vomiting syndrome in children
Journal of Pediatric Gastroenterology and Nutrition · 2025
DOI: 10.1002/jpn3.70020 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Katja Karrento und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Vomiting. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 201 Literaturangaben. Gefördert von: Cyclic Vomiting Syndrome Association.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Cyclic vomiting syndrome (CVS) is a disorder recognized for its unique intensity of vomiting attacks and inordinate impact on quality of life. There is considerable symptom overlap with migraine. Due to the lack of evidence‐based treatment algorithms, current management strategies vary.
Objective
These evidence‐based guidelines were formulated to replace prior expert consensus recommendations and to assist patients and clinicians in the management of pediatric CVS.
Methods
Guidelines were developed by a multidisciplinary panel of experts and a patient representative who prioritized questions relevant to medical providers and patients. The guidelines were developed based on systematic reviews with assessment of certainty of the evidence, following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, including indirect evidence from pediatric migraine headache literature to strengthen the recommendations in areas with limited evidence. The panel used GRADE Evidence‐to‐Decision frameworks to formulate recommendations, which were subject to public comment.
Results
The panel formulated 16 recommendations on the management of pediatric CVS using nonpharmacological and pharmacological approaches. Recommendations were subdivided into abortive (acute) and prophylactic (preventive) interventions.
Conclusions
A strong recommendation was formulated for the use of anti‐migraine agents in aborting CVS episodes in patients with a personal or family history of migraine. Conditional recommendations for abortive CVS therapies included the use of oral and intravenous (IV) 5‐hydroxytryptamine 3 (5‐HT 3 ) and neurokinin 1 (NK‐1) receptor antagonists and early presentation when requiring IV intervention. Conditional recommendations for prophylactic CVS therapies included nonpharmacological treatments such as trigger avoidance, supplements, and various biobehavioral and neuromodulation interventions. Conditional recommendations for prophylactic pharmacological therapies included the use of beta‐blockers, NK‐1 and 5‐hydroxytryptamine 2A (5‐HT 2A ) receptor antagonists, and tricyclic antidepressants. The panel cautioned regarding potential side effects with several pharmacological agents and the use of anti‐convulsants only in refractory CVS. Systematic Review Registration PROSPERO 2022 CRD42022310108; available at: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022310108 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Department of Psychiatry and Behavioral Sciences, Northwestern Feinberg School of Medicine, Chicago, Illinois, USA.
- Division of Pediatric Gastroenterology, McMaster University, Hamilton, Ontario, Canada.
- Department of Neurology, University of California San Francisco, San Francisco, California, USA.
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Nicklaus Children's Hospital, Miami, Florida, USA.
ORCID-Profile: Katja Karrento
Förderung
- Cyclic Vomiting Syndrome Association
Zitieren
APA
Karrento, K., Rosen, J. M., Tarbell, S. E., Issenman, R. M., Gelfand, A. A., Gamboa, H., Parikh, S., Adams, K., Wiercioch, W., & Li, B. U. K. (2025). North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition 2025 guidelines for management of cyclic vomiting syndrome in children. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70020
Vancouver
Karrento K, Rosen JM, Tarbell SE, Issenman RM, Gelfand AA, Gamboa H, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition 2025 guidelines for management of cyclic vomiting syndrome in children. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70020
BibTeX
@article{Karrento2025,
author = {Karrento, Katja and Rosen, John M and Tarbell, Sally E and Issenman, Robert M and Gelfand, Amy A and Gamboa, Heidi and Parikh, Sumit and Adams, Kathleen and Wiercioch, Wojtek and Li, B U K},
title = {North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition 2025 guidelines for management of cyclic vomiting syndrome in children},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
doi = {10.1002/jpn3.70020}
}
EUVIMED